Scientists investigate drug resistance in ROS1 lung cancer
NCT ID NCT07199959
First seen Oct 01, 2025 · Last updated Jun 12, 2026 · Updated 38 times
Summary
This study aims to understand why some ROS1-positive non-small cell lung cancers stop responding to the drug entrectinib. Researchers will analyze tumor or blood samples from 38 patients who have already taken entrectinib as part of their regular care. By looking at the genetic changes in these samples, they hope to identify the mechanisms of acquired resistance. This is an observational study, meaning no new treatments are being tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university shanghai cancer center
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.